|Company name||Cubist Pharmaceuticals, Inc.|
|Live stock price||[stckqut]CBST[/stckqut]|
|P/E compared to competitors||Fair|
|Confident Investor Rating||Fair|
|Target stock price (TWCA growth scenario)||$47.11|
|Target stock price (averages with growth)||$48.02|
|Target stock price (averages with no growth)||$20.36|
|Target stock price (manual assumptions)||$47.35|
The following company description is from Google Finance: http://www.google.com/finance?q=cbst
Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The Company?s products are used primarily in hospitals, but also may be used in acute care settings, including home infusion and hospital outpatient clinics. As of December 31, 2010, Cubist?s derived all of its revenues from CUBICIN (daptomycin for injection), which is a once-daily, bactericidal, intravenous (I.V.) antibiotic with activity against certain Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (S. aureus), (MRSA). As of December 31, 2010, CUBICIN had been used in the treatment of more than an estimated 1.1 million patients in the United States.
Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in this stock as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns.